Delving into the Latest Updates on SYS-6011 with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

SYS 6011, SYS6011

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

CSPC Megalith Biopharmaceutial Co., Ltd.

Active Organization

CSPC Megalith Biopharmaceutial Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的： 1. 评估SYS6011在晚期实体瘤受试者中的安全性和耐受性 2. 确定SYS6011治疗晚期实体瘤受试者的II期推荐剂量（RP2D）次要目的： 1. 评估SYS6011在晚期实体瘤受试者中的药代动力学（PK）特征 2. 评估SYS6011在晚期实体瘤受试者中的免疫原性 3. 评估SYS6011在晚期实体瘤受试者中的初步有效性探索性目的：探索肿瘤组织CD73表达水平与抗肿瘤活性的相关性

[Translation]

Primary objectives: 1. Evaluate the safety and tolerability of SYS6011 in subjects with advanced solid tumors 2. Determine the Phase II recommended dose (RP2D) of SYS6011 for the treatment of subjects with advanced solid tumors Secondary objectives: 1. Evaluate the pharmacokinetic (PK) characteristics of SYS6011 in subjects with advanced solid tumors 2. Evaluate the immunogenicity of SYS6011 in subjects with advanced solid tumors 3. Evaluate the preliminary efficacy of SYS6011 in subjects with advanced solid tumors Exploratory objectives: Explore the correlation between the expression level of CD73 in tumor tissues and anti-tumor activity

Start Date13 Aug 2024

Sponsor / Collaborator

CSPC Megalith Biopharmaceutial Co., Ltd.

100 Clinical Results associated with SYS-6011

Login to view more data

100 Translational Medicine associated with SYS-6011

Login to view more data

100 Patents (Medical) associated with SYS-6011

Login to view more data

100 Deals associated with SYS-6011

Login to view more data